文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

Ceragenin涂层气管导管减少呼吸机相关性肺炎:前瞻性、纵向、交叉、中断时间实施研究(CEASE VAP研究)

Ceragenin-Coated Endotracheal Tubes for the Reduction of Ventilator-Associated Pneumonia: A Prospective, Longitudinal, Crossover, Interrupted Time, Implementation Study (CEASE VAP Study).
PubMed 文献 · Crit Care Explor · 2026-03-20
一句话结论在重症成人中,Ceragenin涂层气管导管与标准声门下吸引气管导管相比VAP发生率相似(19% vs 15%,校正RR 1.22,95%CI 0.70-2.13,p=0.40),但28天无抗生素天数、无通气天数更多,ICU及住院死亡率更低。

该研究为前瞻性、交叉、中断时间序列实施研究,在加拿大金斯顿一家三级内科-外科ICU纳入260例机械通气成人,其中100例接受Ceragenin涂层气管导管(CSA ETT),160例接受声门下吸引气管导管(SSETT),按四阶段交叉在医院层面交替导管类型。主要终点VAP发生率在CSA ETT组为19/100(19%),SSETT组为24/160(15%),校正RR 1.22(95%CI 0.70-2.13),p=0.40,无统计学显著差异。次要分析显示CSA ETT组28天无抗生素天数更多(14.7±10.4 vs 11.8±10.9,p=0.047)、无通气天数更多(15.7±10.7 vs 12.4±11.5,p=0.03)、ICU死亡率更低(20% vs 36%,p=0.01)、住院死亡率更低(25% vs 43%,p=0.004)。实施可行且临床接受度高,无严重装置相关不良事件。作者结论认为需更大规模随机多中心研究确认。

要点

  • 主要终点VAP发生率:CSA ETT组19/100(19%)vs SSETT组24/160(15%),校正RR 1.22(95%CI 0.70-2.13),p=0.40,无统计学显著差异。
  • 次要终点28天无抗生素天数:CSA ETT组14.7±10.4天 vs SSETT组11.8±10.9天,p=0.047。
  • 次要终点无通气天数:CSA ETT组15.7±10.7天 vs SSETT组12.4±11.5天,p=0.03。
  • ICU死亡率:CSA ETT组20/100(20%)vs SSETT组57/160(36%),p=0.01;住院死亡率:CSA ETT组25/100(25%)vs SSETT组68/160(43%),p=0.004。
  • 实施可行且临床接受度高,无严重装置相关不良事件;作者结论认为需更大规模随机多中心研究确认。

适用人群与场景

  • 纳入260例机械通气成人,其中100例接受CSA ETT,160例接受SSETT。
  • 研究场所为加拿大金斯顿一家三级内科-外科ICU。

处置流程与药物剂量

  • 经过一段导入期后,按四阶段交叉实施研究,在医院层面每个研究阶段交替气管导管类型,患者接受CSA ETT或SSETT。

研究设计与关键结果

  • 研究类型为前瞻性、交叉、中断时间序列实施研究,样本量260例,人群为机械通气成人,干预为CSA ETT(100例),对照为SSETT(160例),主要终点VAP发生率:CSA ETT组19/100(19%)vs SSETT组24/160(15%),校正RR 1.22(95%CI 0.70-2.13),p=0.40。
  • 关键次要终点28天无抗生素天数:CSA ETT组14.7±10.4天 vs SSETT组11.8±10.9天,p=0.047;无通气天数:CSA ETT组15.7±10.7天 vs SSETT组12.4±11.5天,p=0.03。
  • ICU死亡率:CSA ETT组20/100(20%)vs SSETT组57/160(36%),p=0.01;住院死亡率:CSA ETT组25/100(25%)vs SSETT组68/160(43%),p=0.004。
  • 实施可行且临床接受度高,无严重装置相关不良事件。

证据类型、等级与局限

  • 证据类型为前瞻性、交叉、中断时间序列实施研究。
  • 局限:作者结论指出需更大规模随机多中心研究确认发现;原文报告需进一步研究以在更大规模随机多中心研究中确认结果。

对床旁实践的改变

  • 作者结论认为,CSA ETT组VAP发生率与SSETT组相似,但CSA ETT组次要临床结局(包括死亡率)更好。
  • 作者结论认为,该交叉实施研究可行,需进一步研究以在更大规模随机多中心研究中确认发现。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the impact of Ceragenin-coated endotracheal tubes (CSA ETTs) on the incidence of ventilator-associated pneumonia (VAP) in critically ill adults and assess feasibility of conducting a multicenter study.

DESIGN: Prospective, crossover, interrupted time series implementation study.

SETTING: A tertiary, medical-surgical-ICU in Kingston, Ontario, Canada.

PATIENTS: A total of 260 mechanically ventilated adults with 100 receiving CSA ETTs and 160 subglottic suction ETTs (SSETTs).

INTERVENTIONS: After a run-in period, patients received either CSA ETTs or SSETT according to a four-period crossover implementation study. ETT type was alternated at the hospital level during each study period.

MEASUREMENTS AND MAIN RESULTS: The primary outcome was VAP incidence. VAP occurred in 19 of 100 (19%) of patients treated with CSA ETTs and 24 of 160 (15%) with standard ETTs, adjusted relative risk (RR) (95% CI), 1.22 (0.70-2.13), p = 0.40. In secondary analyses, CSA ETT patients had more 28-day antibiotic-free days (mean ± sd: 14.7 ± 10.4 vs.11.8 ± 10.9, p = 0.047), ventilation-free days (15.7 ± 10.7 vs. 12.4 ± 11.5, p = 0.03), and lower ICU (n [%]: 20 (20%) vs. 57 (36%), p = 0.01 and hospital mortality: 25 (25%) vs. 68 (43%), p value of equals to 0.004. The CSA ETT was implemented without major difficulties, and acceptability among clinicians was high. No serious device-related adverse events were reported.

CONCLUSIONS: Although patients treated with CSA ETTs had similar rates of VAP than those receiving SSETT, better secondary clinical outcomes, including mortality occurred with the CSA ETTs. The conduct of this cross-over, implementation study was feasible. There is a need for further research to confirm our findings in a larger, randomized, multicenter study.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Muscedere J, Norman PA, D'Arsigney C, et al. Ceragenin-Coated Endotracheal Tubes for the Reduction of Ventilator-Associated Pneumonia: A Prospective, Longitudinal, Crossover, Interrupted Time, Implementation Study (CEASE VAP Study). Crit Care Explor. 2026. PMID: 41860990. doi:10.1097/CCE.0000000000001382

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。